Navigation Links
MIT researchers see alternative to common colorectal cancer drug
Date:6/17/2008

A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found.

Both compounds are analogues of cisplatin, a potent anticancer agent, but the newly investigated compound, known as cDPCP, may better target colorectal cells, potentially sparing other body tissues from damage.

"This compound, the antitumor properties of which were established in mice over 20 years ago, emerged in our search for platinum anticancer drug candidates with cellular uptake properties analogous or superior to those of oxaliplatin," said Stephen Lippard, the Arthur Amos Noyes Professor of Chemistry at MIT and senior author of a paper on the work appearing in the June 16 online edition of the Proceedings of the National Academy of Sciences.

cDPCP could become an alternative to oxaliplatin, which was approved by the FDA in 2004 and is usually the first therapeutic line of defense against colorectal cancer. More than 100,000 Americans are diagnosed with colorectal cancer every year, making it the fifth most common cancer in the United States, according to the National Cancer Institute.

Oxaliplatin and cisplatin fight tumors by entering the cell nucleus and binding to DNA, damaging it and inducing cell death, said Ryan Todd, a graduate student in chemistry and co-lead author of the paper.

cDPCP kills cells in a similar way. However, the key difference is that while oxaliplatin and cisplatin can enter almost any cell, causing harmful side effects, cDPCP requires the assistance of organic cation transporters (OCTs) embedded in the cell membrane.

That help is required because cDPCP is a positively charged molecule. Working with cultured human cells, the researchers found that cDPCP engages the assistance of OCT1 and OCT2, which are present in the colon. Thus, cDPCP could be specifically targeted to colorectal tumors.

"cDPCP may affect other cells in the body, but there could be greater targeting of colorectal cancer cells because of uptake by the transporters," said graduate student Katherine Lovejoy, co-lead author of the paper.

cDPCP's anticancer activity was first observed in mice 20 years ago, but it was never tested in humans, in part because it was not expected to readily cross cell membranes.

Researchers in Lippard's lab, working with other cancer researchers at MIT, have started studying the effectiveness of cDPCP in mice expressing human colorectal tumors, and they also hope to launch clinical trials in humans.


'/>"/>

Contact: Teresa Herbert
therbert@mit.edu
617-258-5403
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... 12, 2016 , ... According to an article published February 4th ... significant portion of hernia repairs throughout the United States. Commenting on this article, Beverly ... that this trend has not only been expected, but it seems to be a ...
(Date:2/12/2016)... Boca Raton, FL (PRWEB) , ... February 12, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted over 250 members of South Florida’s philanthropic community at ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, owner Tal Rabinowitz ... no time to decompress, Rabinowitz found herself drawn to a casual meditation class while ... on her life, implementing a 20-minute-per-day meditation practice with her team. After her tenure ...
(Date:2/12/2016)... Miami, FL (PRWEB) , ... February 12, 2016 ... ... Workspace as a Service (WaaS), today announced the integration of Clarity Intelligence Platform ... itopia’s channel partners to offer real-time business intelligence (BI) to their small and ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... The Jones ... other communities across eastern Texas, is launching a cooperative charity drive with the Tarrant ... , Serving more than 50,000 individuals and families in need, the Tarrant County Food ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 ... Companion Diagnostics in Personalized Medicine and Cancer Therapy. ... - High-Growth Diagnostic Testing Markets. - Key Diagnostic ... - Molecular Diagnostics in Genetic Testing. - ... Diagnostics Markets. - Over-the-Counter Diagnostic Products World Markets. ...
(Date:2/11/2016)... FRANCISCO , Feb. 11, 2016  Kindred Biosciences, ... on saving and improving the lives of pets, today ... Section of the New Animal Drug Application (NADA) for ... pivotal field study (KB0120) of Zimeta for the control ... the Company. --> --> ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  NOIT™ Research ... a special "Gift of Change" campaign to assist needy ... For every such unit sold between February 10, 2016 ... unit to a needy family. The NOIT is an ... non/limited-verbal autistic individuals develop language skills. ...
Breaking Medicine Technology: